[Pericardioversion and catheter ablation use of rivaroxaban in light of X-VERT and VENTURE-AF trials].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Akıllı R; Demir M; Demir M
  • Source:
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir [Turk Kardiyol Dern Ars] 2017 Sep; Vol. 45 (Suppl 4), pp. 15-23.
  • Publication Type:
    Journal Article; Review
  • Language:
    Turkish
  • Additional Information
    • Transliterated Title:
      X-VERT ve VENTURE-AF çalışmalarının verileri ışığında kardiyoversiyon ve kateter ablasyonda rivaroksaban kullanımı.
    • Source:
      Publisher: Kare Country of Publication: Turkey NLM ID: 9426239 Publication Model: Print Cited Medium: Internet ISSN: 1308-4488 (Electronic) Linking ISSN: 10165169 NLM ISO Abbreviation: Turk Kardiyol Dern Ars Subsets: MEDLINE
    • Publication Information:
      Publication: 2023- : İstanbul, Turkey : Kare
      Original Publication: İstanbul : Türk Kardiyoloji Derneği
    • Subject Terms:
      Anticoagulants*/administration & dosage ; Anticoagulants*/therapeutic use ; Catheter Ablation* ; Electric Countershock* ; Rivaroxaban*/administration & dosage ; Rivaroxaban*/therapeutic use; Atrial Fibrillation/therapy ; Humans ; Thromboembolism/drug therapy ; Thromboembolism/prevention & control
    • Abstract:
      Atrial fibrillation (AF) is the most common persistent cardiac arrhythmia and causes mortality in the community. Cardioversion and catheter ablation are frequently used methods for rhythm control. Oral anticoagulants have been used for many years in the prevention of thromboembolic complications in patients with AF. Both cardioversion and catheter ablation have been associated with certain complication risks especially thromboembolism, which can be significantly reduced by adequate anticoagulation. In this review, we discuss the efficacy and safety parameters of continuous rivaroxaban treatmentn compared with dose-adjusted vitamin K antagonist therapy in patients who were planned to undergo cardioversion and catheter ablation according to the data of X-VERT and VENTUREAF trials.
    • Accession Number:
      0 (Anticoagulants)
      9NDF7JZ4M3 (Rivaroxaban)
    • Publication Date:
      Date Created: 20170927 Date Completed: 20180702 Latest Revision: 20181023
    • Publication Date:
      20221213
    • Accession Number:
      10.5543/tkda.2017.27632
    • Accession Number:
      28947726